Biologic & Genetic Medicine Developers

Own developers of antibody, protein, RNA and gene-based medicines rather than research-tool suppliers or healthcare intermediaries. Established biologic franchises provide commercial foundations alongside companies developing genetic treatments for underserved diseases. The approaching earnings calendar offers an opportunity to reassess product demand and pipeline execution, while clinical setbacks, reimbursement pressure and patent competition remain central risks. Launch basket (equal weight): ABBV, AMGN, LLY, MRK, MRNA, REGN, ALNY, BMRN, CRSP, RARE Rules: 1. No inverse, leveraged or volatility ETFs. 2. Only names tradable at the enrolled brokers (Moomoo): no OTC listings, no dead tickers, nothing on the refused list.